Preoperative predictors of blood transfusion in colorectal cancer surgery

被引:0
作者
Kent R. Nilsson
Sean M. Berenholtz
Todd Dorman
Elizabeth Garrett
Pamela Lipsett
Howard S. Kaufman
Peter J. Pronovost
机构
[1] The Johns Hopkins University Schools of Medicine and Hygiene and Public Health,Department of Anesthesiology/CCM
[2] The Johns Hopkins University Schools of Medicine and Hygiene and Public Health,Department of Surgery
[3] The Johns Hopkins University Schools of Medicine and Hygiene and Public Health,Department of Medicine
[4] The Johns Hopkins University Schools of Medicine and Hygiene and Public Health,Department of Oncology
[5] The Johns Hopkins University Schools of Medicine and Hygiene and Public Health,Department of Health Policy and Management
[6] The Johns Hopkins University School of Medicine,Department of Anesthesiology/CCM
来源
Journal of Gastrointestinal Surgery | 2002年 / 6卷
关键词
Colorectal cancer; blood transfusion; outcomes;
D O I
暂无
中图分类号
学科分类号
摘要
Transfusion is associated with multiple risks and morbidities. Little is known, however, about preoperative predictors of transfusion in gastrointestinal surgery patients. To identify factors that influence transfusion practices, we analyzed hospital discharge data from colorectal cancer surgery patients in Maryland between 1994 and 2000 (n = 14,052). The primary outcome variable was whether or not patients received a blood product (“Any Transfusion”). Characteristics independently associated with an increased risk of receiving Any Transfusion included: advanced age (>80 yr: OR 2.3; 95% CI 1.9-2.9; 70–79 yr: OR 1.6; 95% CI 1.4-2.0 vs. <60 yr), moderate to severe liver disease (OR 2.5; 95% CI 1.5-4.2), mild liver disease (OR 2.1; 95% CI 1.5-2.9), diabetes with complications (OR 2.1; 95% CI 1.6-2.6), chronic renal disease (OR 2.1; 95% CI 1.4-3.0), female gender (OR 1.3; 95% CI 1.2-1.5), chronic pulmonary disease (COPD) (OR 1.3; 95% CI 1.1-1.4), and metastatic disease (OR 1.2; 95% CI 1.1-1.4). Patients at hospitals with an annual case volume in the highest quartile were at an increased risk for receiving Any Transfusion (OR 2.1; 95% CI 1.3-3.4) and those with surgeons in the highest volume quartile (>12 cases/yr) were at a decreased risk (OR 0.8; 95% CI 0.6-0.99). The association between greater surgeon case volume and low transfusion rates was seen in all but the very high volume hospitals (>74 cases/yr). Blood product transfusion was associated with a 2.5-fold (95% CI 2.1-3.1) increased mortality, 3.7 day (95% CI 2.1-3.1) increase in hospital length of stay, and a $7120 (95% CI $6472-$7769) increase in total charges compared to patients that did not receive Any Transfusion. This data can be used by providers in discussions with patients regarding the risks for transfusion and in identifying patients in whom strategies to reduce transfusions should be evaluated.
引用
收藏
页码:753 / 762
页数:9
相关论文
共 88 条
[1]  
Goodnough LT(1999)Transfusion medicine. First of two parts: Blood transfusion NEJM 340 438-447
[2]  
Brecher ME(1988)Perioperative red blood cell transfusion JAMA 260 2700-2703
[3]  
Kanter MH(1992)Practice strategies for elective red blood cell transfusion Ann Intern Med 116 403-406
[4]  
AuBuchon JP(1999)A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care NEJM 340 409-417
[5]  
Hebert PC(2000)Eliminating blood transfusions: New aspects and perspectives Anesthesiology 93 242-255
[6]  
Wells G(1999)Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair Transfusion 39 694-700
[7]  
Blajchman M(1999)Transfusion of buffy coat-depleted blood components and risk of postoperative infection in orthopedic patients Transfusion 39 625-632
[8]  
Spahn DR(1992)A clinical and immunologic study of blood transfusion and postoperative bacterial infection in spinal surgery Transfusion 32 517-524
[9]  
Casutt M(1998)Blood transfusion immunomodulation: The silent epidemic Arch Pathol Lab Med 122 117-119
[10]  
Carson JL(1995)Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States N Engl J Med 333 1721-1725